Related content

EZN-2208 (PEG-SN38), A 40 kDa Polyethylene Glycol (PEG) Conjugate, As an Anticancer Agent: Review of Preclinical and Clinical Data

By  

Current Bioactive Compounds, Vol. 7, Iss. 1, 2011-01 ,pp. : 3-7

Bentham Science Publishers

Access to resources Recommend Favorite

A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors

By Nock Charles   Brell Joanna   Bokar Joseph   Cooney Matthew   Cooper Brenda   Gibbons Joseph   Krishnamurthi Smitha   Manda Sudhir   Savvides Panayiotis   Remick Scot   Ivy Percy   Dowlati Afshin  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 126-130

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 trial of Anvirzel™ in patients with refractory solid tumors

By Mekhail Tarek   Kaur Hanspreet   Ganapathi Ram   Budd G.   Elson Paul   Bukowski Ronald  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 423-427

Springer Publishing Company

Access to resources Recommend Favorite

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

By Wu Huali   Infante Jeffrey   Keedy Vicki   Jones Suzanne   Chan Emily   Bendell Johanna   Lee Wooin   Zamboni Beth   Ikeda Satoshi   Kodaira Hiroshi   Rothenberg Mace   Burris Howard   Zamboni William  

European Journal of Clinical Pharmacology, Vol. 69, Iss. 12, 2013-12 ,pp. : 2073-2081

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors

By Kalmadi S.   Davis M.   Dowlati A.   O’Keefe S.   Cline-Burkhardt M.   Pelley R.   Borden E.   Dreicer R.   Bukowski R.   Mekhail T.  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 211-216

Springer Publishing Company

Access to resources Recommend Favorite